» Articles » PMID: 37291618

Determinants of Adverse Reactions to First-line Antitubercular Medicines: a Prospective Cohort Study

Overview
Date 2023 Jun 8
PMID 37291618
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The success of tuberculosis treatment relies on patients adhering to their medication regimen consistently. However, adherence levels tend to decrease among patients who experience adverse drug reactions to antitubercular medications, leading to suboptimal treatment outcomes. Hence, this study aimed to examine the types, incidence rates, and severity of adverse reactions caused by first-line antitubercular drugs. Additionally, it aimed to identify factors associated with the development of these reactions. By doing so, the study aimed to facilitate the provision of personalized and effective treatment to patients, ultimately improving treatment outcomes.

Methods: Newly diagnosed patients with active tuberculosis were monitored from the start of their treatment until the completion of therapy. Any adverse reactions to anti-TB drugs that they encountered were carefully recorded. The collected data were analyzed using appropriate statistical methods such as analysis of variance, Chi-squared test, Fisher's exact test, and independent t-tests. Logistic regression was employed to assess the association between adverse drug reactions and various socio-demographic and clinical factors of the patients, using odds ratios as a measure of association.

Results: Among the 378 patients included in the study, 181 individuals (47.9%) reported experiencing at least one adverse drug reaction, with an incidence rate of 1.75 events per 100-person months. The majority of these reactions occurred during the intensive phase of treatment. The gastrointestinal tract was the most commonly affected system, followed by the nervous system and skin. Patients aged over 45 years (OR = 1.55, 95% CI 1.01-2.39, p = 0.046) and those with extrapulmonary tuberculosis (OR = 2.41, 95% CI 1.03-5.64) were more likely to develop gastrointestinal reactions. Female gender was a significant predictor of both skin (OR = 1.78, 95% CI 1.05-3.02, p = 0.032) and nervous system (OR = 1.65, 95% CI 1.07-2.55, p = 0.024) reactions. Additionally, alcohol use and HIV infection were identified as independent predictors of adverse drug reactions affecting all three systems.

Conclusion: Significant risk factors for developing antitubercular drug adverse reactions include alcohol consumption, cigarette smoking, being HIV positive, female gender and extrapulmonary tuberculosis.

Citing Articles

Sex-dependent variability of isoniazid and rifampicin serum levels in patients with tuberculosis.

Idris R, Dayani A, Groh A, Mohr A, Koepsell J, Zielbauer A Infection. 2024; .

PMID: 39531129 DOI: 10.1007/s15010-024-02424-5.


Influence of sex on the exposure to isoniazid in patients with pulmonary tuberculosis.

Rivera J, Alberio C, Vieira J Rev Inst Med Trop Sao Paulo. 2023; 65:e56.

PMID: 37878973 PMC: 10588987. DOI: 10.1590/S1678-9946202365056.

References
1.
Cunningham G, Dodd T, Grant D, McMurdo M, RICHARDS R . Drug-related problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment. Age Ageing. 1997; 26(5):375-82. DOI: 10.1093/ageing/26.5.375. View

2.
Gupta R, Lucas S, Fielding K, Lawn S . Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015; 29(15):1987-2002. PMC: 4568896. DOI: 10.1097/QAD.0000000000000802. View

3.
Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-Montoya A, Nunez-Garbin A . Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru. PLoS One. 2011; 6(11):e27610. PMC: 3217998. DOI: 10.1371/journal.pone.0027610. View

4.
Chung S, Byeon S, Choi J . Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System. J Korean Med Sci. 2022; 37(16):e128. PMC: 9039191. DOI: 10.3346/jkms.2022.37.e128. View

5.
Breen R, Miller R, Gorsuch T, Smith C, Schwenk A, Holmes W . Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006; 61(9):791-4. PMC: 2117099. DOI: 10.1136/thx.2006.058867. View